NEW YORK and MAINZ, Germany, June 27, 2024 Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency's Emergency Task Force (ETF) to update COVID-19 vaccines to target the SARS-CoV-2 variant JN.1 for the 2024-2025 vaccination campaign. ETF stated that evidence indicates that targeting JN.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve. 1, 2
The European Commission (EC) will review the CHMPs recommendation and is expected to make a final decision soon. Following the EC decision, the updated vaccine will be available to ship to applicable EU member states immediately. Pfizer and BioNTech have been manufacturing the Omicron JN.1-adapted monovalent COVID-19 vaccine at risk to ensure supply readiness ahead of the upcoming fall and winter season when the demand for COVID-19 vaccination is expected to increase.3
The CHMPs recommendation is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the COVID-19 vaccines by Pfizer and BioNTech. The application also included manufacturing and pre-clinical data showing that the JN.1-adapted monovalent COVID-19 vaccine generates a substantially improved response against multiple Omicron JN.1 sublineages, including KP.2, KP.3 and other currently circulating sublineages, compared with the companies Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.4
Pfizer and BioNTech are starting rolling applications with the U.S. Food and Drug Administration (FDA), per recent FDA recommendation, requesting approval of their Omicron KP.2-adapted monovalent COVID-19 vaccines for individuals 6 months of age and older. The companies will continue to monitor the evolving epidemiology of COVID-19 and make appropriate preparations to meet global public health needs.
The COVID-19 vaccines (COMIRNATY) by Pfizer and BioNTech are based on BioNTechs proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines (COMIRNATY Original/Omicron BA.4-5; COMIRNATY Omicron XBB.1.5) in the United States, the European Union, the United Kingdom, and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.
AUTHORIZED USE IN THE EU: COMIRNATY has been granted standard marketing authorization (MA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from the age of 6 months. The vaccine is administered as a single dose in people 5 years of age and older, and as a three-dose series, in infants and children from 6 months to 4 years who have not had COVID-19 with the first two doses are given three weeks apart, followed by a third dose given at least 8 weeks after the second dose. Adults and adolescents from the age of 12 are given 30 micrograms per dose; children aged 5 to 11 years are given 10 micrograms per dose; infants and children aged 6 months to 4 years are given 3 micrograms per dose. Additional doses may be administered to individuals aged 5 years and older who are severely immunocompromised in accordance with national recommendations. The European Medicines Agencys (EMAs) Committee for Medicinal Products for Human Use (CHMP) has completed its rigorous evaluation of COMIRNATY, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are available.
In addition, COMIRNATY has also been granted standard MA for two adapted vaccines: COMIRNATY Original/Omicron BA.4-5, which contains mRNA encoding for the spike protein of the wild-type and of the Omicron BA.4/BA.5 subvariant of SARS-CoV-2; and COMIRNATY Omicron XBB.1.5, which contains mRNA encoding for the spike protein of the Omicron XBB.1.5 subvariant of SARS-CoV-2.
COMIRNATY Omicron XBB.1.5 may be administered as a single dose regardless of prior vaccination status in people aged 5 years and older. Children from 6 months to 4 years of age may have one or three doses depending on whether they have completed a primary vaccination course or have had COVID-19. There should be an interval of at least 3 months between administration of COMIRNATY Original/Omicron BA.4-5 or COMIRNATY Omicron XBB.1.5 and the last prior dose of a COVID-19 vaccine.
IMPORTANT SAFETY INFORMATION
The black equilateral triangle denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or via the website http://www.biontech.de
About Pfizer: Breakthroughs That Change Patients Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website atwww.Pfizer.com. In addition, to learn more, please visit us onwww.Pfizer.comand follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook atFacebook.com/Pfizer.
Pfizer Disclosure Notice The information contained in this release is as of June 27, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizers efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162b2 mRNA vaccine program, and the Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) including an Omicron-adapted monovalent COVID-19 vaccine candidate, based on the JN.1 lineage, including a submission to the European Medicines Agency (EMA) for an Omicron-adapted monovalent COVID-19 vaccine, based on the JN.1 lineage, expectations regarding the demand for COVID-19 vaccines, planned regulatory submissions, qualitative assessments of available data, potential benefits, expectations for clinical trials, potential regulatory submissions, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including Phase 1/2/3 or Phase 4 data), including the data discussed in this release for BNT162b2, any monovalent or bivalent vaccine candidates or any other vaccine candidate in the BNT162 program in any of our studies in pediatrics, adolescents, or adults or real world evidence, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies, in real world data studies or in larger, more diverse populations following commercialization; the ability of BNT162b2, any monovalent or bivalent vaccine candidates or any future vaccine to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when submissions to request emergency use or conditional marketing authorizations for BNT162b2 in additional populations, for a potential booster dose for BNT162b2, any monovalent or bivalent vaccine candidates or any potential future vaccines (including potential future annual boosters or re-vaccination), and/or other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2, any monovalent or bivalent vaccine candidates or any other potential vaccines that may arise from the BNT162 program, including a potential variant-based, higher dose, or bivalent vaccine, and if obtained, whether or when such emergency use authorizations or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including any requested amendments to the emergency use or conditional marketing authorizations), any monovalent or bivalent vaccine candidates (including the submission to the EMA for an Omicron-adapted monovalent COVID-19 vaccine candidate, based on the JN.1 lineage), or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccines benefits outweigh its known risks and determination of the vaccines efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist or not meet expectations which may lead to reduced revenues or excess inventory on-hand and/or in the channel which, for our COVID-19 vaccine, resulted in significant inventory write-offs in 2023 and could continue to result in inventory write-offs, or other unanticipated charges; challenges related to the transition to the commercial market for our COVID-19 vaccine; uncertainties related to the publics adherence to vaccines, boosters, treatments or combinations; risks related to our ability to accurately predict or achieve our revenue forecasts for our COVID-19 vaccine or any potential future COVID-19 vaccines; potential third-party royalties or other claims related to our COVID-19 vaccine; the risk that other companies may produce superior or competitive products; risks related to the availability of raw materials to manufacture or test a vaccine; challenges related to our vaccines formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant-based vaccines; the risk that we may not be able to maintain or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizers business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available atwww.sec.govandwww.pfizer.com.
About BioNTech Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visitwww.BioNTech.com.
BioNTech Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not be limited to, statements concerning: BioNTechs efforts to combat COVID-19; the collaboration between BioNTech and Pfizer; the rate and degree of market acceptance of BioNTechs COVID-19 vaccine, including the Omicron JN.1-adapted adapted monovalent COVID-19 vaccine; qualitative assessments of available data and expectations of potential benefits, including the adapted vaccines response against multiple Omicron JN.1 sublineages, including KP.2, KP.3 and other currently circulating sublineages; regulatory submissions and regulatory approvals or authorizations and expectations regarding manufacturing, distribution and supply; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment; and expected regulatory recommendations to adapt vaccines to address new variants or sublineages. In some cases, forward-looking statements can be identified by terminology such as will, may, should, expects, intends, plans, aims, anticipates, believes, estimates, predicts, potential, continue, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTechs control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTechs pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTechs initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the availability of raw materials to manufacture a vaccine; our vaccines formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery; competition from other COVID-19 vaccines or related to BioNTechs other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; the timing of and BioNTechs ability to obtain and maintain regulatory approval for BioNTechs product candidates; the ability of BioNTechs COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTechs and its counterparties ability to manage and source necessary energy resources; BioNTechs ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTechs third-party collaborators to continue research and development activities relating to BioNTechs development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTechs development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of BioNTechs COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTechs and its collaborators ability to commercialize and market BioNTechs COVID-19 vaccine and, if approved, its product candidates; BioNTechs ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTechs ability to effectively scale BioNTechs production capabilities and manufacture BioNTechs products, including BioNTechs target COVID-19 vaccine production levels, and BioNTechs product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading Risk Factors in BioNTech's Report on Form 6-K for the period ended March 31, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SECs website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
CONTACT
Pfizer: Media Relations +1 (212) 733-1226 PfizerMediaRelations@pfizer.com
Investor Relations +1 (212) 733-4848 IR@pfizer.com
BioNTech: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de
Investor Relations Victoria Meissner, M.D. +1 617 528 8293 Investors@biontech.de
---------- 1 World Health Organization (WHO) Statement on the antigen composition of COVID-19 vaccines. 26 April 2024. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines#:~:text=In%20May%202023%2C%20the%20TAG,1.5%2C%20as%20the%20vaccine%20antigen (Accessed 26.06.2024).
2 European Medicines Agency (EMA) ETF recommends updating COVID-19 vaccines to target new JN.1 variant. 30 April 2024. Available at: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant (Accessed 26.06.2024).
3 European Medicines Agency (EMA) ETF recommends updating COVID-19 vaccines to target new JN.1 variant. 30 April 2024. Available at: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant (Accessed 26.06.2024).
4 Vaccines and Related Biological Products Advisory Committee June 5, 2024 Meeting Presentation- Pfizer/BioNTech Clinical and Preclinical Supportive Data 2024-2025 COVID19 Vaccine Formula. https://www.fda.gov/media/179144/download (Accessed 26.06.2024).
Read more here:
- Booster dose of the Pfizer-BioNTech/BNT162b2 COVID19 vaccine | IDR - Dove Medical Press [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox vaccines have arrived in Victoria. Here's how the rollout will work - ABC News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- UHD, H-E-B Offering Students Bacterial Meningitis Vaccine On Campus With Deferred Payment Option - UHD News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative... [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Japan plans booster shots of Omicron vaccine in October | The Asahi Shimbun: Breaking News, Japan News and Analysis - [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- EyeGene to conduct vaccine projects with government support - KBR [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox Vaccine: Where to Get It - countynewscenter.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccines for Covid-19 arent required in schools this fall - Vox.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- 600 in Wisconsin receive monkeypox vaccination, says health department - Green Bay Press Gazette [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan |... [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Why Monkeypox Vaccine Shortage May Threaten the Immunocompromised - The New York Times [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- UK will run out of monkeypox vaccine in 10 to 20 days - The Guardian [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19 - UMN News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Phillys monkeypox vaccine shortages arent solved yet as feds make move to increase access to the shots - The Philadelphia Inquirer [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Vaccines are now approved for children aged six months to five years, but what about newborn babies? - ABC News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Bottling the monkeypox vaccine could take until early 2023 - POLITICO [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- The Brazilian Scientists Inventing An mRNA Vaccine And Sharing The Recipe : Short Wave - NPR [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 2,000 Monkeypox Vaccine Appointments Are Available in Chicago This Weekend. Here's How to Get One - NBC Chicago [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 'Vaccine fatigue' could hit autumn Covid boosters | News | The Sunday Times - The Times [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Q&A: The new COVID vaccine booster is coming. Should you get it? - The Lawton Constitution [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Former CRH surgeon who survived polio disheartened by vaccination lapses - The Republic [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- 'Only the beginning': Hundreds protest Western University vaccine mandate - CBC.ca [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine hesitancy and trust in health experts: Shifting the focus - Medical News Today [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- I Was There When: AI helped create a vaccine - MIT Technology Review [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- The USDA is sprinkling fish-flavored vaccines from the sky to fight rabies - CNN [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- COVID-19 Vaccines | FDA [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Novavax COVID-19 vaccine available for ages 12 and up; CDC Community Level back at Low - Communications and Outreach - New Hanover County [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine Definition & Meaning - Merriam-Webster [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- National health agency apologises over Covid vaccine ads it was ordered to remove - RNZ [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Editorial: How Jewish space lasers and vaccine nanobots seized the brains of GOP voters - St. Louis Post-Dispatch [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Novel HER2-hICD Vaccine to be Investigated for Treatment of HER2-Low Breast Cancer - Targeted Oncology [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Brazilian Covid vaccine to be tested in humans in 2023 - The Brazilian Report [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer - Cureus [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- City Offering Second Doses of Monkeypox Vaccine to New Yorkers and Begin Accepting Walk-In Appointments - nyc.gov [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Monkeypox vax has disproportionately gone to white Philadelphians. This clinic sought to balance that. - The Philadelphia Inquirer [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Hopeful New Entry In The Race For A Universal Covid Vaccine - Forbes [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Study raises concerns about the effectiveness of the monkeypox vaccine - STAT [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- newsroom.heart.org [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Did the affordable, no-patent COVID vaccine Corbevax live up to its promise? : Goats and Soda - NPR [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- In CDC Survey of Over 13,000 Children, More Than Half Had 'Systemic Reaction' After COVID-19 Vaccine - The Epoch Times [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Department of Health working with community to administer monkeypox vaccines - Honolulu Star-Advertiser [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Fact check: Post-vaccine hospitalization odds not 3 times higher as ex-Japan PM claimed - The Mainichi - The Mainichi [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Impact of vaccinia virus-based vaccines on the 2022 monkeypox virus outbreak - News-Medical.Net [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Microsoft and Unicef drive Covid-19 vaccine roll-out with COVAX platform - Technology Record [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- School Mask, Vaccine Mandates Are Mostly Gone. But What if the Virus Comes Back? - The 74 [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in... [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Getting a Grip on Influenza: The Pursuit of a Universal Vaccine (Part 4) - Forbes [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Why So Few Young Kids Are Vaccinated against COVIDAnd How to Change That - Scientific American [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- UK Travel Vaccine Market Report 2022: Increasing Travel and Tourism & Growing Incidences of Infectious Diseases Fuel Sector -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- At long last, we might have an HIV vaccine - Big Think [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- The associations between vaccination status, type, and time since vaccination with lineage identity during the emergence of new SARS-CoV-2 variants -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Needle-less COVID-19 vaccine developed at Washington University approved for use in India - KSDK.com [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Study: COVID-19 Vaccine Prevented Approximately 27 Million Infections in US Adults - Pharmacy Times [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Health System Warns Exemptions to COVID Vaccines May Expire With New Options - Medpage Today [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Does Moderna's vaccine IP lawsuit herald the end of the pandemic? - Medical Marketing and Media [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- The Unintended Consequences of COVID-19 Vaccine Policy The Wire Science - The Wire Science [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Astrocytes, the Covid vaccine and the 2021 classification - Brain Tumour Research [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Nearly 50 Members of Congress Call on Pentagon to End Military Vaccine Mandate - The Epoch Times [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- New Omicron-fighting Covid vaccine supplied with flimsy needles across Scotland to get replacement syringes - STV News [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Is There A Minimum Age for the Shingles Vaccine? - Healthline [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samples the United Kingdom of Great Britain and Northern Ireland and... [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 850 more unvaxxed NYC teachers, aides fired for not complying with mandate - New York Post [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 'India's vaccine growth story' book review: Far from being a dry collection of facts and figures - The New Indian Express [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Health care workers appeal dismissal of lawsuit over Maine's vaccine mandate - Kennebec Journal and Morning Sentinel [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Department of Health Expands Eligibility for the Monkeypox Vaccine - Anne Arundel County Department of Health [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Could This Be Pfizer's Next Billion-Dollar Vaccine? - The Motley Fool [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Many Vaccinated Youth Who Suffered Heart Inflammation Had Abnormal MRI Results Months Later: CDC Study - The Epoch Times [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Second vaccine doses to be offered to those at highest risk from monkeypox - GOV.UK [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies - Nature.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Coronavirus Roundup: A CDC Team Is Honored for Its Vaccine Distribution Work - GovExec.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Everything to know about the Monkeypox vaccine | Health - Red and Black [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- The U.S. ordered 171 million updated COVID booster shots but only 4.4 million went into arms as Biden says the pandemic is over - Fortune [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Why mosquitoes were the vaccinators in a new malaria vaccine trial : Goats and Soda - NPR [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Lyme disease is on the rise. Why is there still no vaccine? - AAMC [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia - Canada NewsWire [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- 130 people have received incorrect doses of COVID-19 vaccines: MOH - CNA [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Health unit hosts pop-up vaccine clinics throughout the week - BradfordToday [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Doctor who gave anti-vaccine speech in front of effigies of officials being hanged faces discipline hearing - CBC.ca [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- What's really happening with global vaccine access? - Gavi, the Vaccine Alliance [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Study confirms link between COVID-19 vaccination and temporary increase in menstrual cycle length - National Institutes of Health (.gov) [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
